Elite Pharmaceuticals, Inc.
ELTP
$0.5475
-$0.0074-1.33%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 113.85% | 78.26% | -7.56% | 33.36% | 109.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 113.85% | 78.26% | -7.56% | 33.36% | 109.39% |
| Cost of Revenue | 25.72% | 49.54% | -2.97% | 38.56% | 144.20% |
| Gross Profit | 221.26% | 113.04% | -13.09% | 27.15% | 78.39% |
| SG&A Expenses | 70.98% | -8.93% | 58.72% | 47.60% | 20.56% |
| Depreciation & Amortization | -7.24% | 7.61% | 25.91% | 28.45% | 29.67% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.91% | 35.29% | 10.50% | 25.86% | 102.48% |
| Operating Income | 461.57% | 242.14% | -68.92% | 80.99% | 141.20% |
| Income Before Tax | -166.55% | 866.79% | -11,196.71% | -248.32% | -34.62% |
| Income Tax Expenses | 2,193.32% | 270.67% | 129.88% | 108.59% | 49.68% |
| Earnings from Continuing Operations | -1,055.62% | 411.07% | -1,641.89% | -173.90% | -46.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,055.62% | 411.07% | -1,641.89% | -173.90% | -46.07% |
| EBIT | 461.57% | 242.14% | -68.92% | 80.99% | 141.20% |
| EBITDA | 415.05% | 221.42% | -60.52% | 73.36% | 122.23% |
| EPS Basic | -1,016.67% | 381.82% | -1,557.14% | -170.07% | -45.45% |
| Normalized Basic EPS | -160.00% | 916.67% | -463.64% | -229.41% | -37.50% |
| EPS Diluted | -1,766.67% | 15,800.00% | -1,557.14% | -203.00% | -45.45% |
| Normalized Diluted EPS | -160.00% | 916.67% | -463.64% | -229.41% | -37.50% |
| Average Basic Shares Outstanding | 0.01% | 4.84% | 5.27% | 5.36% | 5.36% |
| Average Diluted Shares Outstanding | -0.73% | 3.28% | 4.28% | 4.80% | 6.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |